Literature DB >> 23574794

Poor outcome of HIV-infected patients with plasmablastic lymphoma: results from the German AIDS-related lymphoma cohort study.

Philipp Schommers1, Christoph Wyen, Marcus Hentrich, Daniel Gillor, Alexander Zoufaly, Bjoern Jensen, Johannes R Bogner, Jan Thoden, Jan C Wasmuth, Gerd Fätkenheuer, Christian Hoffmann.   

Abstract

Out of 302 AIDS-related lymphoma (ARL) patients enrolled in the German ARL cohort study, 18 patients had plasmablastic lymphoma (PBL). Twelve out of 18 patients (67%) have died with a median survival of 4 months (range 0-11 months). In univariate analysis, an intermediate or high international prognostic index score was associated with a significantly lower overall survival and progression-free survival. The predominant cause of death was progressive lymphoma (67%). Our data indicate that the outcome of AIDS-related PBL is still very poor.

Entities:  

Mesh：

Year:  2013        PMID： 23574794     DOI： 10.1097/QAD.0b013e32835e069d

Source DB:  PubMed          Journal:  AIDS        ISSN： 0269-9370            Impact factor:   4.177


  8 in total

1.  Primary central nervous system plasmablastic lymphoma in an HIV-positive patient.

Authors:  Ruben Rhoades; Jerald Gong; Neil Palmisiano; Onder Alpdogan
Journal:  BMJ Case Rep       Date:  2019-03-14

2.  Durable complete remission with combination chemotherapy and bortezomib in HIV-associated plasmablastic lymphoma.

Authors:  Nivedita Arora; Arjun Gupta; Navid Sadeghi
Journal:  BMJ Case Rep       Date:  2017-10-09

3.  Clinicopathologic features of plasmablastic lymphoma: Single-center series of 8 cases from Saudi Arabia.

Authors:  Ghaleb Elyamany; Ali Matar Alzahrani; Muna Aljuboury; Najlah Mogadem; Nagham Rehan; Omar Alsuhaibani; Abdulaziz Alabdulaaly; Eman Al-Mussaed; Imad Elhag; Abdullah AlFiaar
Journal:  Diagn Pathol       Date:  2015-06-25       Impact factor: 2.644

4.  Incidence and risk factors for relapses in HIV-associated non-Hodgkin lymphoma as observed in the German HIV-related lymphoma cohort study.

Authors:  Philipp Schommers; Daniel Gillor; Marcus Hentrich; Christoph Wyen; Timo Wolf; Mark Oette; Alexander Zoufaly; Jan-Christian Wasmuth; Johannes R Bogner; Markus Müller; Stefan Esser; Alisa Schleicher; Björn Jensen; Albrecht Stoehr; Georg Behrens; Alexander Schultze; Jan Siehl; Jan Thoden; Ninon Taylor; Christian Hoffmann
Journal:  Haematologica       Date:  2018-02-08       Impact factor: 9.941

5.  Performance of international prognostic indices in plasmablastic lymphoma: a comparative evaluation.

Authors:  Hanno M Witte; Niklas Gebauer; Nadine Hertel; Hartmut Merz; Heinz-Wolfram Bernd; Veronica Bernard; Axel Künstner; Hauke Busch; Nikolas von Bubnoff; Alfred C Feller
Journal:  J Cancer Res Clin Oncol       Date:  2021-03-03       Impact factor: 4.553

6.  Bortezomib, Lenalidomide and Dexamethasone Combination Induced Complete Remission in Relapsed/Refractory Plasmablastic Lymphoma: Case Report of a Potential Novel Treatment Approach.

Authors:  Waleed Sabry; Yue Wu; Shruthi Ganeshappa Kodad
Journal:  Curr Oncol       Date:  2022-07-18       Impact factor: 3.109

7.  Targeting CD38 with Daratumumab Plus Chemotherapy for Patients with Advanced-Stage Plasmablastoid Large B-Cell Lymphoma.

Authors:  Yun Kyoung Ryu; Edd C Ricker; Craig R Soderquist; Mark A Francescone; Andrew H Lipsky; Jennifer E Amengual
Journal:  J Clin Med       Date:  2022-08-22       Impact factor: 4.964

Review 8.  The Changing Landscape of Lymphoma Associated with HIV Infection.

Authors:  Kai Hübel
Journal:  Curr Oncol Rep       Date:  2020-08-15       Impact factor: 5.075
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.